Navigation Links
DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
Date:4/15/2008

Data shows non-invasive assay effectively identifies melanoma

LA JOLLA, Calif., April 15 /PRNewswire/ -- DermTech, a biotechnology company developing molecular diagnostics for the early detection of melanoma and other diseases, will present data at the American Association of Cancer Research on its non-invasive assay that distinguishes melanoma from benign moles. The study entitled: "A Non-invasive Genomic Assay for the Detection of Melanoma in Suspicious Pigmented Nevi", shows that the assay has 100% sensitivity and 90.6% specificity. The biomarker based on 20 target genes is being developed as part of the company's proprietary molecular-based approach that uses its EGIR(TM) (Epidermal Genetic Information Retrieval) technology to identify melanoma at the earliest stages of disease. The late breaking abstract #LB-221 will be presented at Poster Session 19 on Tuesday, April 15.

DermTech's EGIR ("tape stripping") method is based on applying a custom adhesive strip to the skin's surface to obtain RNA and subsequently using gene expression profiling techniques to identify disease.

"Results of this study suggest that the malignant melanocyte, directly or indirectly, induces an alteration in stratum corneum gene expression," said Sherman Chang, PhD, Director of Molecular Biology, DermTech. "These findings pave the way for the development of an objective assay based on genomic data -- a major advance over today's subjective method of identifying disease."

Although melanoma accounts for more than 70% of skin cancer deaths, when detected early it is considered highly curable. In current clinical practice, the detection of melanoma is based upon visual clinical cues including the "ABCDE" criteria for pigmented nevi and results of optical imaging techniques, such as dermoscopy and con-focal microscopy. However, depending upon the setting, only 1 to 10% of lesions biopsied for suspicion of melanoma are positive upon histopathologic examinat
'/>"/>

SOURCE DermTech
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
2. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. Kline Study: Better Brushing Habits Boost European Oral Care Sales
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. NASA study will help stop stowaways to Mars
8. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ewswire-Asia/ -- The pharma and biotech sectors ar...anies are facing significant,pressure to change wi... calls for,lower prices and a greater regulatory b...l crisis have made the work of creating new drugs ... being forced to globalize their R&D,operation...
(Date:11/9/2009)...RNewswire/ -- Following the provision of clinical,...stration (FDA), privately,owned UK company Daval I...al.com ) has been informed that its innovative,ant...n Orphan-Drug,designation for the treatment of Amy...also known as Lou Gehrig,s disease, is the most co...
(Date:11/6/2009)...RNewswire-FirstCall/ -- BioSpecifics Technologies ...y developing first-in-class collagenase-based prod...e third quarter ended September 30, 2009. ,, "... year, the FDA,s Arthritis Advisory Committee unan...al of XIAFLEX(TM) for the treatment of Dupuytren,s...
(Date:11/6/2009)...v. 6 Calbiotech, Inc. announced to...vative Research (SBIR) Phase I contract by the U.S...r terms of the agreement, Calbiotech will develop ... of Dengue virus. ,, Dengue virus is a mosqu... to military forces deployed to tropical areas of ...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in Shanghai 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 2Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 3Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 4Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 5Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results 6Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2
...NAPOLIS, and CAMBRIDGE, Mass., May 5 Amylin Pha...nd Company (NYSE: LLY ) and Alkermes, Inc. (Nasd...cation (NDA) for exenatide once weekly has been su...FDA). Exenatide once weekly is an investigational ...hat is injected subcutaneously and administered on...
...SCO, Calif., May 5 Rigel Pharmaceuticals, Inc. (N...or the first quarter ended March 31, 2009. , , Fo...loss of $29.9 million, or $0.82 per share, compare...re, in the first quarter of 2008. Weighted average... and 2008 were 36.7 million and 34.4 million, resp...
...hallenges separate haves and have-nots and acceler... Despite worldwide economic turmoil, the global b...performance in 2008, according to Beyond borders:...ung,s 23rd annual report on the biotech industry. ...t is placing the business model that fueled biotec...
Other Biology Technology:Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 2Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 3Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 4Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 5Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 6Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes 7Rigel Announces First Quarter 2009 Financial Results 2Rigel Announces First Quarter 2009 Financial Results 3Rigel Announces First Quarter 2009 Financial Results 4Rigel Announces First Quarter 2009 Financial Results 5Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 2Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 3Global Financial Crisis Making Biotech Business Model Unsustainable, According to Ernst & Young 4
(Date:11/9/2009)...ELPHIA, NOVEMBER 9, 2009 A nutritionist whose re...ables to the federal Women, Infants and Children (...Agnes Higgins Award for outstanding achievement in... Harrison, Ph.D., MNS, , a professor in the Depart...y of California, Los Angeles School of Public Heal...
(Date:11/8/2009)...STON - (Nov. 8, 2009) The loss of a gene through ...ssociated with significant abnormalities in learni...led by Baylor College of Medicine ( www.bcm.edu ) ...al Nature Genetics . , "This research goes abou...in a specific group of individuals to this gene," ...
(Date:11/6/2009)...X, Va.Registration is now open for the Society of ...ional Oncology (IO) Therapies" Webinar, which will...anscatheter treatment of liver tumors, kidney tumo...nal organization of physicians, scientists and all...blic health through pioneering advances in image-g...
Breaking Biology News(10 mins):March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Developmental delay could stem from nicotinic receptor deletion 2Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 1Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 2Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 3Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 4Oracle Focuses on Health Sciences Partner Enablement Growth and Accreditation 49591 1Oracle Focuses on Health Sciences Partner Enablement Growth and Accreditation 49591 2Oracle Focuses on Health Sciences Partner Enablement Growth and Accreditation 49591 3Oracle Focuses on Health Sciences Partner Enablement Growth and Accreditation 49591 4Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 1Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 2Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 3
...ce penicillin, a byproduct of a fungal mold, was d...gi for other breakthrough drugs. As reported Jan....m led by a University of Wisconsin-Madison researc...ongoing quest for medically useful compounds in fu...the team, led by professor of plant pathology and ...
...ence is emerging that climate change could reduce ...lso international efforts to cut poverty. However,...dy providing researchers with some of the tools th...oid the worst effects of the problem. , The new kn...wing scientists to both develop new rice varieties...
... 2005 may have been the warmest year in a century,... data from around the world. , Climatologists at N...n New York City noted that the highest global annu...ury was recorded in their analysis for the 2005 ca...udy climate change rank 2005 as the second warmest...
Other Biology News:Mining for gems in the fungal genome 2Mining for gems in the fungal genome 3Climate change: The rice genome to the rescue 2Climate change: The rice genome to the rescue 32005 was the warmest year in a century 2
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
Ribonucleic acid, transfer from baker's yeast (S. cerevisiae) from Sigma-Aldrich
...ct measuring instrument for calibrating single-cha...ompact design and the robust carrying case, the MC... laboratory and on-site at the users premises. The...ual channels are tested automatically. Multi-chann...
...tol DTT White solid.. PACKAGED UNDER INERT GAS. ...action is "driven" to completion. A protective age... found in many other preparations. Blocks the leth... ≥97% by titration. Contaminants: Heavy metal...
Biology Products: